View : 623 Download: 150
Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma
- Title
- Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma
- Authors
- Kim K.H.; Lee H.H.; Yoon Y.E.; Na J.C.; Kim S.Y.; Cho Y.I.; Hong S.J.; Han W.K.
- Ewha Authors
- 김광현
- SCOPUS Author ID
- 김광현
- Issue Date
- 2018
- Journal Title
- Oncotarget
- ISSN
- 1949-2553
- Citation
- Oncotarget vol. 9, no. 1, pp. 662 - 667
- Keywords
- Area under curve; Carcinoma; Early diagnosis; Renal cell
- Publisher
- Impact Journals LLC
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years. © Kim et al.
- DOI
- 10.18632/oncotarget.23087
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
Clinical validation of serum.pdf(746.09 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML